World Class Team
Mr. Huang has over 27 years of executive leadership and investment experience in the Biotech Industry, with a MBA from Stanford University. Since the founding of the Company, Mr. Huang was appointed to be the Executive Chairman, to further grow the Company both as the largest investor’s representative (Kleiner Perkins) and also as a seasoned biotech executive. He is currently Managing Partner at Kleiner Perkins Greater China and Founding Partner at Panacea Venture, as well as Director for the board of multiple biotech companies, both privately and publically listed in the US, China, and Hong Kong.
Mr. Fong has more than 23 years of experience in biotechnology and investment management. He is currently a founding General and Managing Partner of Biomark Capital, a $200+ million life science fund, established in 2013. Prior to forming Biomark Capital, he was with Burrill Capital Management managing life science funds with committed capital over $1 billion. Mr. Fong has played a lead role in over 25 private and public life science financings and currently serves on the boards of directors of a number of private life science companies. Mr. Fong earned his B.A. with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.
Scott Liu, Ph.D.
Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Dr. Liu previously retired from Shanghai Henlius Biotech, Inc. (2696.HK) which he Co-Founded in 2010, held positions as President & CEO, and was integral in building the company to have a valuation of over 20 Billion HKD. Prior to Co-Founding Henlius, he held several executive positions, including Vice President at United Biomedical as well as holding executive positions in quality at Bristol-Myers Squibb and Amgen. Dr. Liu received his Ph.D. degree in Biology from Purdue University with postdoctoral training in Biology at Stanford University.
Ms. Wang has 10 years of investment management and private equity experience. Currently, she is a Vice President at Milestone Capital, responsible for investments in the healthcare and consumer sectors in both public and private equities. Prior to Milestone, Ms. Wang was a private investments analyst at TIFF Investment Management, a not-for-profit organization in Boston, MA, managing portfolios exclusively for endowments and foundations. Ms. Wang holds a B.S. in Applied Mathematics and Economics from Brown University.
Mr. Hsieh has over 20 years of leadership and management experience with a strong expertise in organizational and people development. Since coming on-board in September 2015, he has played a crucial role of attracting and retaining employees at different levels and later appointed by the Board as Chief Compliance Officer to oversee the Company’s Legal & Compliance agenda as well as the operation side. Prior to the Company, Mr. Hsieh was the Chief Marketing and HR Officer at Foxconn Medical Subgroup, SVP of Talent at Standard Chartered Bank Taiwan and Northeast Asia Learning & Talent Development Head for Abbott Labs. Mr. Hsieh graduated from UC Berkeley with a degree in Applied Mathematics.
Allen Ho, Ph.D.
Dr. Ho has more than 20 years of biotech research experience, especially as a seasoned expert in building relations with various Government and Regulatory Agencies including the NMPA, EMEA, US FDA, and AUS with IND filings. Additionally, Dr. Ho has extended assay method development experience as prior to joining the Company, Dr. Ho was Head of Recombinant Protein Therapeutics at PharmaEssentia. Dr. Ho started his career as post-doctoral researcher at Academia Sinica, Taiwan and was later assigned to an integrated structural biology project in Strasbourg, France. Dr. Ho received his Ph.D. in Chemistry from National Cheng-Kung University (Taiwan) and has published various papers in biophysical and biochemical characterizations of proteins.
Jennifer Kuan, Ph.D.
Dr. Kuan has more than 15 years of experience in biotechnology manufacturing with over 10 years in management roles. Her current role is Eden’s Head of Tech Transfer of all processes and leads the entire cGMP Facility in Taiwan. Since joining the Company, Dr. Kuan has successfully led manufacturing operations with zero contamination and batch failures; as well as completed facility and equipment commissioning and qualifications at our previous KUBio site in China with successful 2000L-scale runs. Prior joining the Company, Dr. Kuan was the Plant Manager at PharmaEssentia Corp. in Taichung, Taiwan and she graduated with Ph.D. from Clemson University (USA) in Biosystems Engineering.
Mark Wei, Ph.D.
Dr. Wei serves as Head of Quality Unit, which encompasses the departments of Quality Assurance, Quality Control, Validation, and Formulation Development. He has led Eden to receiving both Taiwan FDA cGMP Certifications (most recent in 2020) as well as inspections from Quality Person(s) of EMEA. Dr. Wei has over 15 years of experience in GMP and Quality systems. He served as the Group Leader of QC with Universe-Medical Biotechnology Co. After receiving his Ph.D. in Biosciences from the University of Nottingham (UK), Dr. Wei had extended international biotech experience as a Researcher in the University of Nottingham.
Ms. Cheng has more than 18 years of Process Development Experience, especially focused on Purification Development and Optimization, along with experience in the building of a GMP Pilot Plant start-up and manufacturing operation experience. She is well known for her expertise in process design, scaling up, and viral clearance validation. Ms. Cheng was promoted to be the Head of Process Development of Eden beginning in 2021 after she joined the company in 2013 as Senior Scientist and absorbed tremendous skills and knowledge during her tenure here. Before joining the Company, Ms. Cheng worked for UBI Asia in purification development and received a Master’s Degree from the College of Nuclear Science at National Tsing Hua University.
Ms. Chen has more than 20 years of finance, accounting and stock affairs experience of which with 5 years in marketing SPOs and executing IPOs emphasizing underwriting businesses. She has particular skills in financial reports analysis, cost analysis, finance planning, management of working capital, expense control, evaluating investments and investor relations. Before joining the Company, she was the senior deputy manager of accounting department at Innolux Corporation.
Mr. Huang has more than 11 years of Global leadership experience in Manufacturing and Operations Excellence and has a background in Industrial and Manufacturing Engineering. For the past several years, he has led the Company in building Strategic Alliances, BD & Licensing, and all Due Diligence activities. Mr. Huang’s biotech experience has supported our team in successfully managing drug/biosimilar projects through Phase III Clinical Trials and bolstered partnership/licensing opportunities. Before joining the Company, Steven was a NPI Product Manager at a manufacturing firm and also worked as an Engineer at Alcon Laboratories.
Ms. Chen, PMP®, is an experienced CMC project manager with more than 12 years’ experience in the pharmaceutical industry. She has managed several pipeline & CDMO projects successfully to the point of IND fillings in the EU/China, with extensive knowledge of the scientific, business, and regulatory aspects of drug/biosimilar development. Ms. Chen is familiar with functional areas beyond CMC, such as Regulatory, Supply Chain, Technical Operations and Clinical Operations. Prior joining the Company, Ms. Chen worked for Sanofi Genzyme as Researcher in the US and received a Master’s Degree of Biology from University of Saint Joseph (US).